Inactive

PRE-SOLICITATION NOTICE **NOTICE OF INTENT TO SOLE SOURCE NOI-NIAID-24-2227153 NAICS – 541380, Testing Services This is a Notice of Intent, not a request for proposal. The National Institute of Allerg... PRE-SOLICITATION NOTICE **NOTICE OF INTENT TO SOLE SOURCE NOI-NIAID-24-2227153 NAICS – 541380, Testing Services This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Infinity Biologix LLC of Piscataway, NJ (dba SAMPLED) to procure Whole Genome Sequencing (WGS) for the NIAID Centralized Sequencing Program. This is to provide gap coverage between an expiring award and new award in process will be a couple months before completion. No other vendors will be considered. The National Institute of Allergy and Infectious Diseases (NIAID) Division of Intramural Research (DIR) scientists study all aspects of infectious diseases, including the causative agent, vectors, and pathogenesis in human and animal hosts. Clinical research is an integral part of this mission, enabling key lab discoveries to be rapidly translated into methods to prevent, diagnose, or treat disease. DIR researchers annually conduct more than 200 clinical trials at the NIH Clinical Center on the Bethesda, Maryland, campus and at collaborating U.S. and international sites. In support of clinical research, the NIAID Centralized Sequencing Program (CSP) is comprehensive program that obtains genetic testing, harmonizes phenotypic and genomic data, performs variant interpretation, and provides clinically validated results for participants enrolled in a diverse set of protocols at the NIH Clinical Center. The goal of the NIAID CSP is both to contribute to the understanding of underlying genetic etiology of disease and to address the clinical need for genomic evaluations. The purpose of this acquisition is to support the mission of DIR to obtain genetic testing for the NIAID CSP. The objective is to purchase long read genome sequencing and associated deliverables. The CSP will have direct implications for the care of NIH patients and for the discovery of disease mechanisms. SCOPE/REQUIREMENTS THAT WILL BE MET FOR THIS GAP COVERAGE AWARD: Long Read Genome Sequencing at 20X depth of coverage – data generation and delivery (N = 40): Long read genome sequencing on PacBio Revio platform Includes data delivery via secure transfer such as AWS, GCP, Globus, Aspera Accept DNA isolated from multiple tissue types, including whole blood, saliva, fibroblast, peripheral blood mononuclear cell (PBMC), and other tissues Delivery of raw unmapped readds, including the following: Raw Data - HiFi Read (.bam/.pbi) QC data Minimum sequencing read depth of 20X coverage SNP trace for sample identity analysis, assessment of contamination, sex, and relationships with other samples Ability to accept small batch sizes, < 50 samples in one batch as well as larger batches of 50-100 samples per batch Results returned within 60 days upon sample receipt Long Read Genome Sequencing at 30X depth of coverage– data generation and delivery (N = 60): Long read genome sequencing on PacBio Revio platform Includes data delivery via secure transfer such as AWS, GCP, Globus, Aspera Accept DNA isolated from multiple tissue types, including whole blood, saliva, fibroblast, peripheral blood mononuclear cell (PBMC), and other tissues Delivery of raw unmapped reads, including the following: Raw data BAM files - HiFi Read (.bam/.pbi) QC data Minimum sequencing read depth of 30X coverage SNP trace for sample identity analysis, assessment of contamination, sex, and relationships with other samples Ability to accept small batch sizes, < 50 samples in one batch as well as larger batches of 50-100 samples per batch Results returned within 60 days upon sample receipt Contractor skills, capacity, and expertise: Contractor displays demonstrated expertise in genetics and genomics and capacity to complete long read genome sequencing. Strong communication and project management skills Desired Deliverables for Long Read Genome Sequencing: Demonstrated consistent recent high-quality data Provision of QC information regarding data quality. Specifically, measures of read quality, median coverage, etc. Provision of sample data upon request, e.g., NA12878, to aid in assessment of control data quality Ability to accept sample information via Excel manifests The required turn-around time for sequencing and receipt of deliverables is 60 days from the time the contractor receives and accessions the samples. Upon start of award, contractor and government team will be required to hold an orientation briefing/kick-off meeting during which specific workflows for sample quantity, volume, concentration range, and quality be reviewed. All controlled vocabulary regarding sample and individual information be covered, as well as processes for submitting orders, tracking order progress, communication about samples, and downloading data. Timely follow up for questions related to contract is to be completed via targeted meetings and/or email communication. Contractor reviews and confirms manifests sent with samples and receipt of samples. Issues with samples due to quality and/or quantity, identity issues, mismatch with manifests, and other issues preventing samples from moving forward in sequencing pipeline be communicated to NIH within 48 hours. Known process issues within contractor lab can be resolved without prior approval from NIH. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. Contact information: NOI-NIAID-22-2227153), Dana Monroe at dana.monroe@nih.gov. NOI posting closes at 5:00pm ET, Friday, July 5, 2024. Any responses received by the closing date of this synopsis will be considered by the Government only if they can proved they can meet every requirement stated herein. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.